Skip to main content

Face of woman with rosacea

Your story matters.

Let’s talk about rosacea.

If you are or think you might be one of the 16 million Americans who are living with Rosacea, then you’ve come to the right place. Rosacea is a persistent inflammatory skin condition. It is characterized by facial redness, bumps and blemishes, eye irritation, and in rare cases, rosacea can cause the skin to thicken and develop a bumpy texture. Rosacea can occur in both men and women, and affects people of all ages but it is most common after the age of 30.1

Learn More

Rosacea Relief Quiz

Do you think you have rosacea?

Take our Rosacea Relief quiz to see if your symptoms may be related to rosacea. We’ll provide you with a guide to discuss it with your dermatologist.

Take the Quiz

One Trusted Family of Brands

Four Effective Rosacea Treatments

Having rosacea can be discouraging, but the good news is that once it has been diagnosed by your healthcare provider, you can learn how to treat it. With the help of Galderma products and your healthcare provider’s guidance, you may find the course of treatment and skin care routine that may work for you.

  • Oracea (doxycycline) Once-daily 40 mg Capsules logo Indicated for the oral treatment of only inflammatory lesions of rosacea.
  • Epsolay (benzoyl peroxide) Cream, 5% logo Indicated for the topical treatment of the inflammatory lesions of rosacea.
  • Soolantra (Ivermectin) Once-daily Cream, 1% logo Indicated for the treatment of inflammatory lesions of rosacea.
  • Mirvaso (brimonidine) topical gel, 0.33% logo Indicated for the topical treatment of persistent (nontransient) facial erythema.

Find Treatment Options

Galderma CareConnect Patient Savings Card

Instant Savings on Galderma Prescriptions

You may save on your prescription with the Galderma CAREConnect Patient Savings Card.**

Learn More

Important Safety Information for ORACEA® (doxycycline) 40 mg* Capsules

Indication: ORACEA® (doxycycline, USP) 40 mg* capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. ORACEA does not lessen the facial redness caused by rosacea. Adverse Events: In controlled clinical studies, the most commonly reported adverse events (>2%) in subjects treated with ORACEA were nasopharyngitis, diarrhea, hypertension and sinusitis. Warnings/Precautions: ORACEA should not be used to treat or prevent infections. ORACEA should not be taken by patients who have a known hypersensitivity to doxycycline or other tetracyclines. ORACEA should not be taken during pregnancy, by nursing mothers, or during tooth development (up to the age of 8 years) and may cause reversible inhibition of bone growth. If Clostridium difficile associated diarrhea (CDAD) occurs, may need to discontinue ORACEA. Although photosensitivity was not observed in clinical trials, ORACEA patients should minimize or avoid exposure to natural or artificial sunlight. The efficacy of ORACEA treatment beyond 16 weeks and safety beyond 9 months have not been established. Click here to view the full prescribing information for ORACEA Capsules.

*30 mg immediate release & 10 mg delayed release beads

Important Safety Information for EPSOLAY® (benzoyl peroxide) Cream, 5%

Indication: EPSOLAY® (benzoyl peroxide) Cream, 5% is indicated for the treatment of inflammatory lesions of rosacea in adults. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in patients treated with EPSOLAY Cream were pain, erythema (redness), pruritus (itching) and edema (swelling), all at the application site. Warnings/Precautions: Patients using EPSOLAY Cream may experience hypersensitivity reactions, including anaphylaxis (acute allergic reaction), angioedema (rapid swelling), and urticaria (hives). If serious hypersensitivity reaction occurs, discontinue use of EPSOLAY Cream immediately and seek medical attention/initiate appropriate therapy. Skin Irritation/contact dermatitis may be experienced, including erythema (redness), scaling, dryness, and stinging/burning. Irritation and contact dermatitis may occur. Use a moisturizer and discontinue EPSOLAY Cream if symptoms do not improve. Avoid application to cuts, abrasions, eczematous, or sunburned skin. EPSOLAY Cream may increase photosensitivity, sensitivity to ultraviolet light. Minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment). Use sunscreen or protective clothing when sun exposure cannot be avoided. Discontinue use of EPSOLAY Cream at the first evidence of sunburn.

Important Safety Information for SOOLANTRA® (ivermectin) Cream, 1%

Indication: SOOLANTRA Cream is indicated for the treatment of inflammatory lesions of rosacea. Not for oral, ophthalmic or intravaginal use. Adverse Events: In clinical trials with SOOLANTRA Cream, the most common adverse reactions (incidence ≤ 1 %) included skin burning sensation and skin irritation.

Important Safety Information for MIRVASO® (brimonidine) topical gel, 0.33%

Indication: MIRVASO Gel is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older. Adverse Events: In clinical trials, the most common adverse reactions (≥1%) included erythema, flushing, skin burning sensation and contact dermatitis. Warnings/Precautions: MIRVASO Gel should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud’s phenomenon, orthostatic hypotension, thromboangiitis obliterans, scleroderma, or Sjögren’s syndrome. Alpha‐2 adrenergic agents can lower blood pressure. MIRVASO Gel should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease. Serious adverse reactions following accidental ingestion of MIRVASO Gel by children have been reported. Keep MIRVASO Gel out of reach of children. Not for oral, ophthalmic, or intravaginal use. Click here to view full prescribing information for MIRVASO Gel.

Each gram of gel contains 5 mg of brimonidine tartrate, equivalent to 3.3 mg of brimonidine free base.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

Select a Brand for Prescribing and Safety Information:

*30 mg immediate release & 10 mg delayed release beads
†Each gram of gel contains 5 mg of brimonidine tartrate, equivalent to 3.3 mg of brimonidine free base.

**The Galderma® CAREConnect Program (“Program”) is brought to you by Galderma Laboratories, L.P. (“Galderma”). The Program is only available at participating pharmacies for patients with commercial insurance or patients without insurance. Patients who are enrolled in a state or federal government run or government sponsored healthcare plan can not participate in the Program. Any claim under the Program must be submitted by participating pharmacies to one of the Administrators of the Program.

The Program is subject to applicable state and federal law and is void where prohibited by law, rule or regulation. In the event a lower cost generic drug that the FDA has designated as a therapeutic equivalent product is available for one of the Galderma products covered by the Program, or if the active ingredient of a Galderma product is available at a lower cost without a prescription, this offer will become void in California with respect to the Galderma product.

Insurance eligibility criteria will differ by plan. Patients are responsible for verifying their insurance eligibility criteria.